Back to News
Market Impact: 0.2
Maravai LifeSciences Holdings Consensus Price Target Increased 11.84% to $8.67
Source: Nasdaq
Analyst EstimatesAnalyst InsightsHealthcare & Biotech
The average one-year price target for Maravai LifeSciences rose 11.84% to $8.67 per share from $7.75, based on aggregate analyst targets. The prior estimate was dated September 29, 2026; the article provides no share-price reaction or additional analyst rationale.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
MRVI0.20
More News
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- SpaceX bear flips to big bull because of AI business. Analyst now sees 70% gain
- Oncologists Cheer Melanoma Data
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- Williams Trading cuts Deckers Outdoor stock price target on weak DTC trends
- Investing.com’s stocks of the week
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Options, Earnings Call Transcripts, AI Chat, Bookmarks & More
- AI Tools for Family Offices: A Stack by Decision Type